The Evolving Treatment Landscape for Metastatic Differentiated Thyroid Cancer

por Grande, Carolyn, Brose, Marcia S.
Publicado 2014

The Challenges of Clinical Research in Rare Cancers: Bevacizumab Use in Low-Grade Serous Ovarian and Primary Peritoneal Cancers

por Grande, Carolyn, Visovsky, Constance, Brose, Marcia S.
Publicado 2017

Ectopic Cushing’s Syndrome and Severe Hypocalcemia Due to Medullary Thyroid Cancer Responsive to Selpercatinib

por Turin, Christie Gloria, Brose, Marcia S, White, Caitlin A
Publicado 2021

Population Pharmacokinetics and Exposure–Response Analysis for the Phase 3 COSMIC-311 Trial of Cabozantinib for Radioiodine-Refractory Differentiated Thyroid Cancer

por Ly, Neang S., Li, Jing, Faggioni, Raffaella, Roskos, Lorin K., Brose, Marcia S.
Publicado 2023

Lack of BRAF mutations in hyalinizing trabecular neoplasm

por Baloch, Zubair W, Puttaswamy, Kanchan, Brose, Marcia, LiVolsi, Virginia A
Publicado 2006

Timing of multikinase inhibitor initiation in differentiated thyroid cancer

por Brose, Marcia S, Smit, Johannes, Lin, Chia-Chi, Pitoia, Fabian, Fellous, Marc, DeSanctis, Yoriko, Schlumberger, Martin, Tori, Masayuki, Sugitani, Iwao
Publicado 2017

Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III...

por Huillard, Olivier, Jouinot, Anne, Tlemsani, Camille, Brose, Marcia S., Arrondeau, Jennifer, Meinhardt, Gerold, Fellous, Marc, De Sanctis, Yoriko, Schlumberger, Martin, Goldwasser, Francois
Publicado 2019

THE RET/PTC-3 ONCOGENE ACTIVATES CLASSICAL NF-κB BY STABILIZING NIK

por Neely, Robert J., Brose, Marcia S., Gray, Carolyn M., McCorkell, Kelly A., Leibowitz, Jason M, Ma, Changqing, Rothstein, Jay L., May, Michael J.
Publicado 2010

Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced o...

por Brose, Marcia S, Nutting, Christopher M, Sherman, Steven I, Shong, Young Kee, Smit, Johannes WA, Reike, Gerhard, Chung, John, Kalmus, Joachim, Kappeler, Christian, Schlumberger, Martin
Publicado 2011

MON-521 An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib (LEN) for the Treatment of Anaplastic Thyroid Cancer (ATC)

por Wirth, Lori J, Brose, Marcia S, Sherman, Eric J, Misir, Soamnauth, Xie, Sharon, Almonte, Ana, Ye, Weifei, Licitra, Lisa, Schlumberger, Martin, Sherman, Steven I, Cabanillas, Maria
Publicado 2020

LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer

por Wirth, Lori J, Brose, Marcia S, Elisei, Rossella, Capdevila, Jaume, Hoff, Ana O, Hu, Mimi I, Tahara, Makoto, Robinson, Bruce, Gao, Ming, Xia, Meng, Maeda, Patricia, Sherman, Eric
Publicado 2022

Exposure–Response Modeling and Simulation of Progression‐Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer

por Grevel, Joachim, Jentsch, Garrit, Austin, Rupert, Prins, Nicolaas H., Lettieri, John, Mitchell, David, Huang, Funan, Brose, Marcia S., Schlumberger, Martin, Meinhardt, Gerold, Peña, Carol E. A., Ploeger, Bart A.
Publicado 2019

A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update

por Makker, Vicky, Aghajanian, Carol, Cohn, Allen L., Romeo, Margarita, Bratos, Raquel, Brose, Marcia S., Messing, Mark, Dutta, Lea, Dutcus, Corina E., Huang, Jie, Schmidt, Emmett V., Orlowski, Robert, Taylor, Matthew H.
Publicado 2023

Cabozantinib for previously treated radioiodine‐refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC‐311 trial

por Brose, Marcia S., Robinson, Bruce G., Sherman, Steven I., Jarzab, Barbara, Lin, Chia‐Chi, Vaisman, Fernanda, Hoff, Ana O., Hitre, Erika, Bowles, Daniel W., Sen, Suvajit, Oliver, Jennifer W., Banerjee, Kamalika, Keam, Bhumsuk, Capdevila, Jaume
Publicado 2022

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer

por Mehnert, Janice M., Varga, Andrea, Brose, Marcia S., Aggarwal, Rahul R., Lin, Chia-Chi, Prawira, Amy, de Braud, Filippo, Tamura, Kenji, Doi, Toshihiko, Piha-Paul, Sarina A., Gilbert, Jill, Saraf, Sanatan, Thanigaimani, Pradeep, Cheng, Jonathan D., Keam, Bhumsuk
Publicado 2019

A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer

por Brose, Marcia S, Panaseykin, Yury, Konda, Bhavana, de la Fouchardiere, Christelle, Hughes, Brett G M, Gianoukakis, Andrew G, Joo Park, Young, Romanov, Ilia, Krzyzanowska, Monika K, Leboulleux, Sophie, Binder, Terri A, Dutcus, Corina, Xie, Ran, Taylor, Matthew H
Publicado 2021

Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer

por Worden, Francis, Fassnacht, Martin, Shi, Yuankai, Hadjieva, Tatiana, Bonichon, Françoise, Gao, Ming, Fugazzola, Laura, Ando, Yuichi, Hasegawa, Yasuhisa, Park, Do Joon, Shong, Young Kee, Smit, Johannes W A, Chung, John, Kappeler, Christian, Meinhardt, Gerold, Schlumberger, Martin, Brose, Marcia S
Publicado 2015

Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib

por Yang, James C. H., Brose, Marcia S., Castro, Gilberto, Kim, Edward S., Lassen, Ulrik N., Leyvraz, Serge, Pappo, Alberto, López-Ríos, Fernando, Reeves, John A., Fellous, Marc, Penault-Llorca, Frédérique, Rudzinski, Erin R., Tabatabai, Ghazaleh, Vassal, Gilles, Drilon, Alexander, Trent, Jonathan
Publicado 2022

Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer

por Wirth, Lori J., Brose, Marcia S., Sherman, Eric J., Licitra, Lisa, Schlumberger, Martin, Sherman, Steven I., Bible, Keith C., Robinson, Bruce, Rodien, Patrice, Godbert, Yann, De La Fouchardiere, Christelle, Newbold, Kate, Nutting, Christopher, Misir, Soamnauth, Xie, Ran, Almonte, Ana, Ye, Weifei, Cabanillas, Maria E.
Publicado 2021

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

por Makker, Vicky, Taylor, Matthew H., Aghajanian, Carol, Oaknin, Ana, Mier, James, Cohn, Allen L., Romeo, Margarita, Bratos, Raquel, Brose, Marcia S., DiSimone, Christopher, Messing, Mark, Stepan, Daniel E., Dutcus, Corina E., Wu, Jane, Schmidt, Emmett V., Orlowski, Robert, Sachdev, Pallavi, Shumaker, Robert, Casado Herraez, Antonio
Publicado 2020